| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Uterine Cervical Neoplasms | 30 | 2025 | 350 | 9.470 |
Why?
|
| Early Detection of Cancer | 33 | 2025 | 428 | 6.790 |
Why?
|
| Breast Neoplasms | 45 | 2025 | 1679 | 5.780 |
Why?
|
| Neoplasms | 25 | 2025 | 1341 | 4.740 |
Why?
|
| Health Knowledge, Attitudes, Practice | 20 | 2025 | 959 | 4.200 |
Why?
|
| Education, Nursing | 6 | 2023 | 20 | 3.920 |
Why?
|
| Egypt | 45 | 2025 | 53 | 2.940 |
Why?
|
| Rural Population | 17 | 2025 | 352 | 2.720 |
Why?
|
| Middle Aged | 99 | 2025 | 11819 | 2.640 |
Why?
|
| Mass Screening | 15 | 2025 | 531 | 2.580 |
Why?
|
| Female | 127 | 2025 | 24018 | 2.410 |
Why?
|
| Humans | 153 | 2025 | 42163 | 2.380 |
Why?
|
| Urban Population | 15 | 2025 | 364 | 2.270 |
Why?
|
| Adult | 88 | 2025 | 13458 | 2.170 |
Why?
|
| Tanzania | 18 | 2023 | 26 | 2.130 |
Why?
|
| Papillomavirus Infections | 9 | 2025 | 363 | 2.050 |
Why?
|
| Aged | 64 | 2025 | 7982 | 1.980 |
Why?
|
| Registries | 19 | 2019 | 431 | 1.940 |
Why?
|
| Health Personnel | 4 | 2025 | 262 | 1.800 |
Why?
|
| Patient Acceptance of Health Care | 12 | 2025 | 471 | 1.700 |
Why?
|
| Incidence | 29 | 2025 | 1054 | 1.570 |
Why?
|
| Poverty | 8 | 2025 | 395 | 1.540 |
Why?
|
| Neoplasm Staging | 14 | 2025 | 366 | 1.530 |
Why?
|
| Young Adult | 36 | 2025 | 4936 | 1.410 |
Why?
|
| Patient Education as Topic | 4 | 2019 | 234 | 1.390 |
Why?
|
| Mammography | 8 | 2025 | 211 | 1.370 |
Why?
|
| Colorectal Neoplasms | 7 | 2025 | 502 | 1.360 |
Why?
|
| Needs Assessment | 3 | 2019 | 180 | 1.320 |
Why?
|
| Mentors | 5 | 2021 | 143 | 1.210 |
Why?
|
| Education, Professional | 2 | 2019 | 9 | 1.110 |
Why?
|
| Morocco | 15 | 2025 | 16 | 1.070 |
Why?
|
| Papillomaviridae | 4 | 2025 | 136 | 1.060 |
Why?
|
| Students | 6 | 2021 | 617 | 1.020 |
Why?
|
| Delayed Diagnosis | 3 | 2019 | 33 | 1.000 |
Why?
|
| Artificial Intelligence | 2 | 2024 | 94 | 0.980 |
Why?
|
| Pancreatic Neoplasms | 7 | 2010 | 206 | 0.960 |
Why?
|
| Neoplasm Recurrence, Local | 4 | 2016 | 150 | 0.950 |
Why?
|
| Developing Countries | 7 | 2021 | 112 | 0.950 |
Why?
|
| Receptors, Estrogen | 7 | 2019 | 177 | 0.940 |
Why?
|
| Arabs | 4 | 2014 | 19 | 0.940 |
Why?
|
| Case-Control Studies | 19 | 2020 | 1266 | 0.900 |
Why?
|
| Papillomavirus Vaccines | 4 | 2021 | 168 | 0.900 |
Why?
|
| Adolescent | 30 | 2025 | 5950 | 0.890 |
Why?
|
| Specimen Handling | 1 | 2025 | 61 | 0.880 |
Why?
|
| Problem-Based Learning | 2 | 2021 | 41 | 0.870 |
Why?
|
| Medical Records | 4 | 2019 | 48 | 0.850 |
Why?
|
| Epidemiology | 2 | 2016 | 9 | 0.830 |
Why?
|
| Health Policy | 1 | 2025 | 184 | 0.820 |
Why?
|
| Education, Graduate | 2 | 2016 | 30 | 0.810 |
Why?
|
| Self Care | 1 | 2025 | 173 | 0.810 |
Why?
|
| Aged, 80 and over | 19 | 2025 | 2803 | 0.780 |
Why?
|
| Biomedical Research | 3 | 2016 | 467 | 0.780 |
Why?
|
| Universities | 3 | 2021 | 539 | 0.750 |
Why?
|
| Ovarian Neoplasms | 2 | 2016 | 406 | 0.710 |
Why?
|
| Environmental Exposure | 7 | 2015 | 247 | 0.690 |
Why?
|
| Breast Neoplasms, Male | 4 | 2014 | 8 | 0.690 |
Why?
|
| Referral and Consultation | 3 | 2020 | 141 | 0.690 |
Why?
|
| Prostatic Neoplasms | 3 | 2024 | 1068 | 0.680 |
Why?
|
| Students, Medical | 2 | 2021 | 153 | 0.680 |
Why?
|
| Male | 42 | 2025 | 22779 | 0.680 |
Why?
|
| Tunisia | 7 | 2022 | 7 | 0.670 |
Why?
|
| Colombia | 3 | 2025 | 30 | 0.670 |
Why?
|
| Uterine Cervical Dysplasia | 1 | 2020 | 41 | 0.670 |
Why?
|
| Age Distribution | 14 | 2025 | 249 | 0.660 |
Why?
|
| rho GTP-Binding Proteins | 3 | 2011 | 27 | 0.660 |
Why?
|
| Lymphatic Metastasis | 3 | 2024 | 81 | 0.650 |
Why?
|
| Retrospective Studies | 15 | 2021 | 2485 | 0.650 |
Why?
|
| Education, Medical, Undergraduate | 1 | 2021 | 93 | 0.650 |
Why?
|
| Michigan | 11 | 2018 | 52 | 0.640 |
Why?
|
| Risk Factors | 23 | 2021 | 3942 | 0.610 |
Why?
|
| Adenocarcinoma | 5 | 2012 | 287 | 0.610 |
Why?
|
| Hepatitis C, Chronic | 3 | 2015 | 44 | 0.600 |
Why?
|
| Neoplasms, Glandular and Epithelial | 2 | 2016 | 57 | 0.590 |
Why?
|
| Genes, ras | 3 | 2007 | 25 | 0.580 |
Why?
|
| Genes, p53 | 3 | 2007 | 28 | 0.580 |
Why?
|
| Vaginal Smears | 4 | 2013 | 62 | 0.580 |
Why?
|
| Receptor, erbB-2 | 2 | 2019 | 149 | 0.570 |
Why?
|
| Uterine Neoplasms | 1 | 2019 | 51 | 0.570 |
Why?
|
| Medicine, African Traditional | 2 | 2014 | 8 | 0.550 |
Why?
|
| HIV Infections | 5 | 2021 | 2535 | 0.540 |
Why?
|
| Minority Health | 3 | 2016 | 96 | 0.540 |
Why?
|
| Minority Groups | 3 | 2021 | 663 | 0.510 |
Why?
|
| Health Education | 4 | 2023 | 358 | 0.510 |
Why?
|
| Carcinoma, Squamous Cell | 4 | 2011 | 187 | 0.510 |
Why?
|
| Indians, North American | 3 | 2014 | 179 | 0.500 |
Why?
|
| Patient Compliance | 3 | 2019 | 225 | 0.500 |
Why?
|
| HIV Seropositivity | 2 | 2015 | 196 | 0.490 |
Why?
|
| Time Factors | 8 | 2021 | 1848 | 0.490 |
Why?
|
| Child | 17 | 2021 | 3381 | 0.490 |
Why?
|
| Liver Cirrhosis | 2 | 2015 | 64 | 0.480 |
Why?
|
| Cystadenocarcinoma, Serous | 1 | 2016 | 44 | 0.480 |
Why?
|
| Age Factors | 10 | 2021 | 1139 | 0.480 |
Why?
|
| Attitude to Health | 3 | 2014 | 336 | 0.470 |
Why?
|
| Models, Economic | 1 | 2014 | 30 | 0.450 |
Why?
|
| Islam | 1 | 2014 | 17 | 0.450 |
Why?
|
| Refugees | 1 | 2014 | 21 | 0.440 |
Why?
|
| Sarcoma, Kaposi | 1 | 2014 | 24 | 0.440 |
Why?
|
| Communication Barriers | 2 | 2012 | 60 | 0.440 |
Why?
|
| Internationality | 2 | 2021 | 38 | 0.430 |
Why?
|
| Cross-Sectional Studies | 10 | 2022 | 3077 | 0.430 |
Why?
|
| SEER Program | 9 | 2025 | 157 | 0.430 |
Why?
|
| Educational Status | 5 | 2021 | 335 | 0.430 |
Why?
|
| Nebraska | 5 | 2020 | 5 | 0.410 |
Why?
|
| Socioeconomic Factors | 7 | 2025 | 1221 | 0.410 |
Why?
|
| Mortality | 2 | 2025 | 174 | 0.410 |
Why?
|
| Mutation | 3 | 2007 | 1169 | 0.410 |
Why?
|
| Hepatitis C | 1 | 2014 | 138 | 0.400 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2016 | 290 | 0.400 |
Why?
|
| United States | 15 | 2025 | 5072 | 0.400 |
Why?
|
| Logistic Models | 11 | 2021 | 1001 | 0.400 |
Why?
|
| Insurance, Health | 3 | 2024 | 143 | 0.390 |
Why?
|
| Antiviral Agents | 1 | 2014 | 189 | 0.390 |
Why?
|
| Follow-Up Studies | 5 | 2016 | 1051 | 0.390 |
Why?
|
| DNA, Neoplasm | 3 | 2009 | 92 | 0.380 |
Why?
|
| Prognosis | 5 | 2018 | 850 | 0.380 |
Why?
|
| Quality of Health Care | 1 | 2013 | 158 | 0.370 |
Why?
|
| Reproducibility of Results | 5 | 2024 | 1058 | 0.370 |
Why?
|
| Survival Rate | 5 | 2018 | 353 | 0.370 |
Why?
|
| DNA Methylation | 3 | 2013 | 393 | 0.370 |
Why?
|
| Health Status Disparities | 2 | 2018 | 705 | 0.360 |
Why?
|
| Career Choice | 1 | 2011 | 51 | 0.350 |
Why?
|
| Molecular Epidemiology | 5 | 2011 | 58 | 0.330 |
Why?
|
| International Cooperation | 1 | 2010 | 51 | 0.330 |
Why?
|
| Education, Medical | 3 | 2012 | 117 | 0.320 |
Why?
|
| Zambia | 3 | 2021 | 47 | 0.320 |
Why?
|
| Smoking | 5 | 2015 | 1019 | 0.320 |
Why?
|
| Anti-HIV Agents | 1 | 2014 | 475 | 0.320 |
Why?
|
| Life Style | 4 | 2015 | 326 | 0.310 |
Why?
|
| Head and Neck Neoplasms | 1 | 2010 | 81 | 0.310 |
Why?
|
| Africa, Northern | 3 | 2020 | 6 | 0.300 |
Why?
|
| Brain Neoplasms | 1 | 2010 | 129 | 0.290 |
Why?
|
| Age of Onset | 2 | 2025 | 115 | 0.280 |
Why?
|
| Multivariate Analysis | 4 | 2013 | 638 | 0.270 |
Why?
|
| Vesicular Transport Proteins | 1 | 2007 | 47 | 0.270 |
Why?
|
| Health Services Accessibility | 4 | 2025 | 680 | 0.270 |
Why?
|
| Carcinoma, Hepatocellular | 1 | 2009 | 158 | 0.270 |
Why?
|
| Environmental Pollution | 1 | 2007 | 26 | 0.270 |
Why?
|
| Cost-Benefit Analysis | 3 | 2018 | 176 | 0.260 |
Why?
|
| Prevalence | 5 | 2021 | 1597 | 0.260 |
Why?
|
| Liver Neoplasms | 1 | 2009 | 211 | 0.260 |
Why?
|
| Environmental Pollutants | 4 | 2013 | 198 | 0.250 |
Why?
|
| Child, Preschool | 8 | 2015 | 1516 | 0.250 |
Why?
|
| Infant | 7 | 2015 | 1143 | 0.250 |
Why?
|
| Occupations | 2 | 2019 | 27 | 0.240 |
Why?
|
| Romania | 1 | 2025 | 6 | 0.240 |
Why?
|
| Occupational Exposure | 3 | 2019 | 89 | 0.230 |
Why?
|
| Nuclear Proteins | 2 | 2006 | 330 | 0.230 |
Why?
|
| Treatment Outcome | 4 | 2019 | 1586 | 0.230 |
Why?
|
| Insurance Benefits | 1 | 2024 | 3 | 0.230 |
Why?
|
| Disease Progression | 2 | 2020 | 661 | 0.230 |
Why?
|
| Quality of Life | 3 | 2014 | 599 | 0.230 |
Why?
|
| Lactation | 2 | 2010 | 44 | 0.220 |
Why?
|
| Pathology | 1 | 2024 | 8 | 0.220 |
Why?
|
| Cell Cycle Proteins | 1 | 2006 | 239 | 0.220 |
Why?
|
| Neoplasm Invasiveness | 3 | 2016 | 284 | 0.210 |
Why?
|
| Diagnostic Imaging | 1 | 2024 | 53 | 0.210 |
Why?
|
| Tobacco Smoke Pollution | 2 | 2022 | 54 | 0.200 |
Why?
|
| Hydrocarbons, Chlorinated | 1 | 2003 | 21 | 0.200 |
Why?
|
| Cervix Uteri | 1 | 2023 | 47 | 0.200 |
Why?
|
| Biopsy | 1 | 2023 | 176 | 0.200 |
Why?
|
| Computers | 1 | 2022 | 35 | 0.200 |
Why?
|
| Insecticides | 1 | 2003 | 54 | 0.200 |
Why?
|
| Intrauterine Devices, Medicated | 1 | 2022 | 12 | 0.190 |
Why?
|
| Levonorgestrel | 1 | 2022 | 17 | 0.190 |
Why?
|
| Kenya | 1 | 2022 | 56 | 0.190 |
Why?
|
| Pregnancy | 3 | 2022 | 1737 | 0.190 |
Why?
|
| Capacity Building | 1 | 2023 | 99 | 0.190 |
Why?
|
| Immunoenzyme Techniques | 2 | 2016 | 111 | 0.190 |
Why?
|
| Program Evaluation | 2 | 2021 | 358 | 0.190 |
Why?
|
| Ghana | 4 | 2014 | 36 | 0.190 |
Why?
|
| Education, Pharmacy | 1 | 2003 | 56 | 0.180 |
Why?
|
| Genetic Predisposition to Disease | 4 | 2017 | 727 | 0.180 |
Why?
|
| Polymerase Chain Reaction | 3 | 2014 | 454 | 0.180 |
Why?
|
| Carcinoma, Lobular | 3 | 2011 | 5 | 0.180 |
Why?
|
| DNA Damage | 1 | 2004 | 358 | 0.180 |
Why?
|
| Oman | 1 | 2021 | 7 | 0.180 |
Why?
|
| Phenols | 2 | 2013 | 102 | 0.180 |
Why?
|
| Colonic Neoplasms | 2 | 2015 | 223 | 0.180 |
Why?
|
| Carcinoma, Ductal, Breast | 3 | 2011 | 31 | 0.180 |
Why?
|
| Focus Groups | 2 | 2014 | 398 | 0.180 |
Why?
|
| Ethiopia | 1 | 2021 | 15 | 0.180 |
Why?
|
| National Cancer Institute (U.S.) | 1 | 2021 | 32 | 0.180 |
Why?
|
| Prospective Studies | 2 | 2016 | 1574 | 0.180 |
Why?
|
| Medical Oncology | 1 | 2021 | 46 | 0.170 |
Why?
|
| Acetic Acid | 1 | 2021 | 19 | 0.170 |
Why?
|
| Faculty | 1 | 2021 | 105 | 0.170 |
Why?
|
| Odds Ratio | 4 | 2019 | 587 | 0.160 |
Why?
|
| Medically Underserved Area | 1 | 2021 | 118 | 0.160 |
Why?
|
| Urinary Bladder Neoplasms | 3 | 2014 | 84 | 0.160 |
Why?
|
| Interviews as Topic | 3 | 2025 | 428 | 0.160 |
Why?
|
| Receptors, Androgen | 2 | 2011 | 144 | 0.160 |
Why?
|
| Learning | 1 | 2021 | 155 | 0.160 |
Why?
|
| Neoplastic Cells, Circulating | 2 | 2011 | 25 | 0.160 |
Why?
|
| Waist Circumference | 1 | 2020 | 90 | 0.160 |
Why?
|
| Population Surveillance | 3 | 2018 | 245 | 0.160 |
Why?
|
| Industry | 1 | 2019 | 30 | 0.150 |
Why?
|
| Vaccination | 1 | 2021 | 332 | 0.150 |
Why?
|
| Schools, Medical | 1 | 2021 | 208 | 0.150 |
Why?
|
| Occupational Diseases | 1 | 2019 | 53 | 0.150 |
Why?
|
| Patient Readmission | 1 | 2021 | 120 | 0.150 |
Why?
|
| Travel | 1 | 2019 | 34 | 0.150 |
Why?
|
| Agriculture | 3 | 2019 | 65 | 0.150 |
Why?
|
| Carcinoma, Transitional Cell | 2 | 2009 | 22 | 0.150 |
Why?
|
| Nutrition Assessment | 1 | 2019 | 79 | 0.150 |
Why?
|
| Perception | 2 | 2021 | 209 | 0.150 |
Why?
|
| Infant, Newborn | 4 | 2010 | 960 | 0.150 |
Why?
|
| Preventive Health Services | 1 | 2019 | 65 | 0.150 |
Why?
|
| Adiposity | 1 | 2020 | 155 | 0.150 |
Why?
|
| Hepatitis B, Chronic | 2 | 2009 | 16 | 0.150 |
Why?
|
| Curriculum | 1 | 2021 | 311 | 0.150 |
Why?
|
| Mental Disorders | 1 | 2022 | 377 | 0.140 |
Why?
|
| Cost Savings | 1 | 2018 | 18 | 0.140 |
Why?
|
| Healthcare Disparities | 2 | 2015 | 573 | 0.140 |
Why?
|
| Physician-Patient Relations | 1 | 2019 | 146 | 0.140 |
Why?
|
| Inflammation | 2 | 2017 | 729 | 0.140 |
Why?
|
| Oxidative Stress | 1 | 2004 | 990 | 0.140 |
Why?
|
| Hospitals | 1 | 2019 | 115 | 0.140 |
Why?
|
| Premenopause | 3 | 2020 | 109 | 0.140 |
Why?
|
| Hair Removal | 1 | 2017 | 1 | 0.140 |
Why?
|
| Vulvar Neoplasms | 1 | 2017 | 10 | 0.140 |
Why?
|
| Health Care Costs | 1 | 2018 | 89 | 0.130 |
Why?
|
| Body Mass Index | 2 | 2020 | 916 | 0.130 |
Why?
|
| Databases, Factual | 2 | 2015 | 336 | 0.130 |
Why?
|
| Burkina Faso | 1 | 2016 | 1 | 0.130 |
Why?
|
| Family | 2 | 2017 | 192 | 0.130 |
Why?
|
| Mexican Americans | 1 | 2019 | 224 | 0.130 |
Why?
|
| Mothers | 1 | 2019 | 212 | 0.130 |
Why?
|
| Breast Diseases | 1 | 2016 | 5 | 0.130 |
Why?
|
| Social Class | 3 | 2013 | 286 | 0.130 |
Why?
|
| Health Resources | 2 | 2013 | 37 | 0.120 |
Why?
|
| Carboplatin | 1 | 2016 | 20 | 0.120 |
Why?
|
| Data Collection | 2 | 2013 | 210 | 0.120 |
Why?
|
| Benzhydryl Compounds | 2 | 2013 | 49 | 0.120 |
Why?
|
| HIV Seronegativity | 1 | 2015 | 41 | 0.120 |
Why?
|
| BRCA2 Protein | 2 | 2017 | 50 | 0.120 |
Why?
|
| Uridine Monophosphate | 1 | 2014 | 1 | 0.110 |
Why?
|
| Decision Trees | 1 | 2014 | 22 | 0.110 |
Why?
|
| Bhutan | 1 | 2014 | 1 | 0.110 |
Why?
|
| Ribavirin | 1 | 2014 | 20 | 0.110 |
Why?
|
| Proportional Hazards Models | 2 | 2018 | 512 | 0.110 |
Why?
|
| Markov Chains | 1 | 2014 | 42 | 0.110 |
Why?
|
| Laparoscopy | 1 | 2015 | 59 | 0.110 |
Why?
|
| Health Behavior | 2 | 2023 | 568 | 0.110 |
Why?
|
| Interferons | 1 | 2014 | 37 | 0.110 |
Why?
|
| National Health Programs | 1 | 2014 | 19 | 0.110 |
Why?
|
| Adenocarcinoma, Mucinous | 2 | 2012 | 24 | 0.110 |
Why?
|
| AIDS-Related Opportunistic Infections | 1 | 2014 | 44 | 0.110 |
Why?
|
| Self Efficacy | 1 | 2015 | 211 | 0.110 |
Why?
|
| Sex Factors | 2 | 2015 | 1008 | 0.110 |
Why?
|
| Drug Therapy, Combination | 1 | 2014 | 233 | 0.110 |
Why?
|
| Insurance Coverage | 1 | 2014 | 108 | 0.110 |
Why?
|
| Radio | 1 | 2013 | 2 | 0.100 |
Why?
|
| Postoperative Complications | 1 | 2015 | 253 | 0.100 |
Why?
|
| Poisson Distribution | 2 | 2010 | 44 | 0.100 |
Why?
|
| South Dakota | 1 | 2013 | 4 | 0.100 |
Why?
|
| North Dakota | 1 | 2013 | 2 | 0.100 |
Why?
|
| Iowa | 1 | 2013 | 9 | 0.100 |
Why?
|
| Air Pollutants | 1 | 2015 | 127 | 0.100 |
Why?
|
| Early Diagnosis | 2 | 2011 | 69 | 0.100 |
Why?
|
| Consumer Health Information | 1 | 2013 | 24 | 0.100 |
Why?
|
| India | 2 | 2010 | 105 | 0.100 |
Why?
|
| Polymorphism, Genetic | 2 | 2011 | 200 | 0.100 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 1 | 2014 | 456 | 0.100 |
Why?
|
| Antiretroviral Therapy, Highly Active | 1 | 2014 | 229 | 0.100 |
Why?
|
| Survival Analysis | 1 | 2014 | 362 | 0.100 |
Why?
|
| Ultrasonography, Mammary | 1 | 2012 | 8 | 0.100 |
Why?
|
| Exercise | 1 | 2018 | 674 | 0.100 |
Why?
|
| Transients and Migrants | 1 | 2013 | 42 | 0.100 |
Why?
|
| Regression Analysis | 2 | 2010 | 487 | 0.100 |
Why?
|
| Rectal Neoplasms | 1 | 2012 | 19 | 0.100 |
Why?
|
| Latin America | 1 | 2012 | 53 | 0.090 |
Why?
|
| Parity | 2 | 2010 | 60 | 0.090 |
Why?
|
| Estrogens, Non-Steroidal | 1 | 2012 | 21 | 0.090 |
Why?
|
| Caribbean Region | 1 | 2012 | 75 | 0.090 |
Why?
|
| Menopause | 2 | 2009 | 63 | 0.090 |
Why?
|
| Telephone | 1 | 2012 | 35 | 0.090 |
Why?
|
| Peru | 1 | 2011 | 40 | 0.090 |
Why?
|
| Women's Health Services | 1 | 2011 | 12 | 0.090 |
Why?
|
| Colonic Polyps | 1 | 2012 | 70 | 0.090 |
Why?
|
| Geography | 1 | 2011 | 107 | 0.090 |
Why?
|
| Women's Health | 2 | 2025 | 158 | 0.090 |
Why?
|
| Breast Self-Examination | 1 | 2011 | 13 | 0.090 |
Why?
|
| Phthalic Acids | 1 | 2011 | 18 | 0.090 |
Why?
|
| Attitude | 1 | 2012 | 108 | 0.090 |
Why?
|
| Combined Modality Therapy | 1 | 2011 | 174 | 0.090 |
Why?
|
| Carcinoma, Papillary | 1 | 2011 | 15 | 0.090 |
Why?
|
| Acculturation | 1 | 2013 | 203 | 0.090 |
Why?
|
| Schistosomiasis | 2 | 2009 | 18 | 0.090 |
Why?
|
| Culture | 1 | 2012 | 172 | 0.090 |
Why?
|
| Practice Guidelines as Topic | 1 | 2012 | 225 | 0.080 |
Why?
|
| Risk Assessment | 4 | 2020 | 845 | 0.080 |
Why?
|
| Middle East | 1 | 2010 | 21 | 0.080 |
Why?
|
| Tobacco, Smokeless | 1 | 2010 | 19 | 0.080 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 2010 | 25 | 0.080 |
Why?
|
| Insulin-Like Growth Factor Binding Protein 3 | 1 | 2010 | 27 | 0.080 |
Why?
|
| Epigenesis, Genetic | 1 | 2013 | 274 | 0.080 |
Why?
|
| Oral Hygiene | 1 | 2010 | 23 | 0.080 |
Why?
|
| Asia | 1 | 2010 | 99 | 0.080 |
Why?
|
| Income | 2 | 2021 | 160 | 0.080 |
Why?
|
| Insulin-Like Growth Factor I | 1 | 2010 | 81 | 0.080 |
Why?
|
| Developed Countries | 1 | 2009 | 15 | 0.080 |
Why?
|
| Neoplasms, Hormone-Dependent | 1 | 2009 | 18 | 0.080 |
Why?
|
| Estradiol Congeners | 1 | 2009 | 2 | 0.080 |
Why?
|
| Feasibility Studies | 1 | 2010 | 238 | 0.080 |
Why?
|
| Carcinoma | 1 | 2010 | 106 | 0.070 |
Why?
|
| Gene Silencing | 1 | 2009 | 154 | 0.070 |
Why?
|
| Pain | 1 | 2011 | 283 | 0.070 |
Why?
|
| Peptides | 1 | 2011 | 357 | 0.070 |
Why?
|
| Epidemiologic Studies | 1 | 2007 | 33 | 0.070 |
Why?
|
| Tissue Array Analysis | 1 | 2007 | 79 | 0.070 |
Why?
|
| Antineoplastic Agents | 1 | 2016 | 979 | 0.070 |
Why?
|
| Qualitative Research | 2 | 2025 | 526 | 0.070 |
Why?
|
| Research Design | 1 | 2009 | 370 | 0.060 |
Why?
|
| Androgens | 1 | 2007 | 107 | 0.060 |
Why?
|
| Exons | 1 | 2006 | 91 | 0.060 |
Why?
|
| Receptors, Progesterone | 3 | 2012 | 90 | 0.060 |
Why?
|
| Knowledge | 1 | 2006 | 16 | 0.060 |
Why?
|
| Education, Medical, Continuing | 1 | 2006 | 35 | 0.060 |
Why?
|
| Chi-Square Distribution | 3 | 2011 | 236 | 0.060 |
Why?
|
| Health Promotion | 1 | 2012 | 691 | 0.060 |
Why?
|
| Carcinoma, Pancreatic Ductal | 1 | 2006 | 60 | 0.060 |
Why?
|
| Reproductive History | 2 | 2020 | 27 | 0.060 |
Why?
|
| Cadmium | 1 | 2006 | 54 | 0.060 |
Why?
|
| Models, Biological | 1 | 2009 | 711 | 0.060 |
Why?
|
| Smoking Cessation | 1 | 2012 | 583 | 0.060 |
Why?
|
| Natural Language Processing | 1 | 2024 | 21 | 0.050 |
Why?
|
| Liver | 1 | 2007 | 503 | 0.050 |
Why?
|
| Physicians | 1 | 2006 | 180 | 0.050 |
Why?
|
| Sex Distribution | 2 | 2015 | 224 | 0.050 |
Why?
|
| Lymphocytes | 1 | 2004 | 124 | 0.050 |
Why?
|
| Gene Expression Regulation, Neoplastic | 1 | 2009 | 933 | 0.050 |
Why?
|
| Students, Dental | 1 | 2022 | 6 | 0.050 |
Why?
|
| Estrogens | 1 | 2004 | 202 | 0.050 |
Why?
|
| Primary Health Care | 1 | 2006 | 362 | 0.050 |
Why?
|
| Cohort Studies | 3 | 2014 | 1729 | 0.050 |
Why?
|
| Sensitivity and Specificity | 2 | 2015 | 602 | 0.050 |
Why?
|
| Linear Models | 1 | 2003 | 311 | 0.050 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2004 | 458 | 0.050 |
Why?
|
| Africa South of the Sahara | 1 | 2021 | 51 | 0.050 |
Why?
|
| Argentina | 1 | 2021 | 14 | 0.040 |
Why?
|
| Cost of Illness | 1 | 2021 | 95 | 0.040 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2021 | 11 | 0.040 |
Why?
|
| Personal Satisfaction | 1 | 2021 | 74 | 0.040 |
Why?
|
| Suicide | 1 | 2022 | 139 | 0.040 |
Why?
|
| Occult Blood | 1 | 2020 | 32 | 0.040 |
Why?
|
| Midwestern United States | 1 | 2019 | 21 | 0.040 |
Why?
|
| Government Programs | 1 | 2019 | 29 | 0.040 |
Why?
|
| Postmenopause | 1 | 2020 | 139 | 0.040 |
Why?
|
| History, 21st Century | 1 | 2019 | 85 | 0.040 |
Why?
|
| Pilot Projects | 2 | 2012 | 733 | 0.040 |
Why?
|
| History, 20th Century | 1 | 2019 | 124 | 0.040 |
Why?
|
| Colonoscopy | 1 | 2019 | 117 | 0.040 |
Why?
|
| Comorbidity | 1 | 2021 | 725 | 0.040 |
Why?
|
| Mexico | 1 | 2019 | 286 | 0.040 |
Why?
|
| Cause of Death | 1 | 2018 | 183 | 0.030 |
Why?
|
| Risk Reduction Behavior | 1 | 2018 | 137 | 0.030 |
Why?
|
| Genitalia, Female | 1 | 2017 | 29 | 0.030 |
Why?
|
| Carcinoma, Medullary | 2 | 2008 | 3 | 0.030 |
Why?
|
| Bulgaria | 1 | 2016 | 1 | 0.030 |
Why?
|
| Europe, Eastern | 1 | 2016 | 3 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2017 | 58 | 0.030 |
Why?
|
| Plasma Cells | 1 | 2016 | 11 | 0.030 |
Why?
|
| Phenotype | 2 | 2011 | 774 | 0.030 |
Why?
|
| Immunosuppressive Agents | 1 | 2016 | 94 | 0.030 |
Why?
|
| Depression | 1 | 2022 | 837 | 0.030 |
Why?
|
| Professional Practice Location | 1 | 2015 | 17 | 0.030 |
Why?
|
| Colectomy | 1 | 2015 | 21 | 0.030 |
Why?
|
| Cyprus | 1 | 2015 | 1 | 0.030 |
Why?
|
| Anxiety | 1 | 2022 | 847 | 0.030 |
Why?
|
| Immunoglobulin G | 1 | 2016 | 253 | 0.030 |
Why?
|
| Europe | 1 | 2015 | 114 | 0.030 |
Why?
|
| Diet | 2 | 2011 | 810 | 0.030 |
Why?
|
| New Jersey | 1 | 2014 | 15 | 0.030 |
Why?
|
| Toxicogenetics | 1 | 2013 | 4 | 0.030 |
Why?
|
| Oncology Service, Hospital | 1 | 2013 | 3 | 0.030 |
Why?
|
| Cytosine | 1 | 2013 | 33 | 0.020 |
Why?
|
| Guanine | 1 | 2013 | 45 | 0.020 |
Why?
|
| Hospitals, Teaching | 1 | 2013 | 33 | 0.020 |
Why?
|
| Chronic Disease | 1 | 2016 | 541 | 0.020 |
Why?
|
| Germany | 1 | 2012 | 24 | 0.020 |
Why?
|
| Cluster Analysis | 1 | 2013 | 206 | 0.020 |
Why?
|
| Diagnosis, Differential | 1 | 2013 | 236 | 0.020 |
Why?
|
| California | 1 | 2014 | 531 | 0.020 |
Why?
|
| Program Development | 1 | 2013 | 237 | 0.020 |
Why?
|
| Health Care Surveys | 1 | 2012 | 152 | 0.020 |
Why?
|
| Cytodiagnosis | 1 | 2011 | 10 | 0.020 |
Why?
|
| Food Packaging | 1 | 2011 | 5 | 0.020 |
Why?
|
| Nigeria | 1 | 2011 | 92 | 0.020 |
Why?
|
| Human Development | 1 | 2011 | 9 | 0.020 |
Why?
|
| Polymorphism, Restriction Fragment Length | 1 | 2011 | 29 | 0.020 |
Why?
|
| Trinucleotide Repeats | 1 | 2011 | 5 | 0.020 |
Why?
|
| Feeding Behavior | 1 | 2015 | 461 | 0.020 |
Why?
|
| Rural Health | 1 | 2011 | 55 | 0.020 |
Why?
|
| Urban Health | 1 | 2011 | 99 | 0.020 |
Why?
|
| Genome-Wide Association Study | 1 | 2013 | 421 | 0.020 |
Why?
|
| DNA, Viral | 1 | 2011 | 323 | 0.020 |
Why?
|
| Pesticides | 1 | 2010 | 59 | 0.020 |
Why?
|
| Religion | 1 | 2009 | 90 | 0.020 |
Why?
|
| Lung Neoplasms | 1 | 2014 | 479 | 0.020 |
Why?
|
| Genotype | 1 | 2011 | 796 | 0.020 |
Why?
|
| Carcinoma in Situ | 1 | 2008 | 16 | 0.020 |
Why?
|
| Schistosomiasis haematobia | 1 | 2008 | 3 | 0.020 |
Why?
|
| Pancreatitis, Chronic | 1 | 2007 | 6 | 0.020 |
Why?
|
| Sex Hormone-Binding Globulin | 1 | 2007 | 25 | 0.020 |
Why?
|
| Liver Function Tests | 1 | 2007 | 19 | 0.020 |
Why?
|
| Serum Albumin | 1 | 2007 | 58 | 0.020 |
Why?
|
| Immunohistochemistry | 1 | 2009 | 928 | 0.020 |
Why?
|
| Ultrasonography | 1 | 2007 | 132 | 0.020 |
Why?
|
| Motor Activity | 1 | 2009 | 438 | 0.020 |
Why?
|
| Diabetes Complications | 1 | 2007 | 99 | 0.020 |
Why?
|
| Testosterone | 1 | 2007 | 211 | 0.020 |
Why?
|
| Carcinoma, Signet Ring Cell | 1 | 2005 | 5 | 0.020 |
Why?
|
| Genes, p16 | 1 | 2005 | 11 | 0.020 |
Why?
|
| Jordan | 1 | 2005 | 24 | 0.020 |
Why?
|
| Turkey | 1 | 2005 | 23 | 0.020 |
Why?
|
| Chromosomal Instability | 1 | 2005 | 20 | 0.020 |
Why?
|
| Microsatellite Repeats | 1 | 2005 | 60 | 0.020 |
Why?
|
| CpG Islands | 1 | 2005 | 107 | 0.010 |
Why?
|
| Sex Characteristics | 1 | 2007 | 253 | 0.010 |
Why?
|
| Gene Frequency | 1 | 2005 | 203 | 0.010 |
Why?
|
| Educational Measurement | 1 | 2006 | 100 | 0.010 |
Why?
|
| Analysis of Variance | 1 | 2006 | 574 | 0.010 |
Why?
|
| Adaptor Proteins, Signal Transducing | 1 | 2005 | 206 | 0.010 |
Why?
|
| Attitude of Health Personnel | 1 | 2006 | 222 | 0.010 |
Why?
|
| Carrier Proteins | 1 | 2005 | 318 | 0.010 |
Why?
|
| Signal Transduction | 1 | 2005 | 2111 | 0.010 |
Why?
|